Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.

Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC
Clin Cancer Res. 2009 15 (14): 4712-21

PMID: 19584166 · PMCID: PMC2819132 · DOI:10.1158/1078-0432.CCR-08-2635

MeSH Terms (25)

Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Apoptosis Breast Neoplasms Cell Line, Tumor Cell Proliferation Diagnostic Imaging Dideoxynucleosides Female Fluorine Radioisotopes Fluorodeoxyglucose F18 Glucose Humans Mammary Neoplasms, Experimental Mice Mice, Nude Mice, Transgenic Positron-Emission Tomography Prognosis Receptor, ErbB-2 Reproducibility of Results Trastuzumab Xenograft Model Antitumor Assays

Connections (3)

This publication is referenced by other Labnodes entities: